Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2015 Oct 6;39(5):471–476. doi: 10.1111/1753-6405.12470

Cancers in Australia attributable to exposure to solar ultraviolet radiation and prevented by regular sunscreen use

Catherine M Olsen 1,2, Louise F Wilson 1, Adele C Green 1,2,3, Christopher J Bain 1,4, Lin Fritschi 5, Rachel E Neale 1,2, David C Whiteman 1,2
PMCID: PMC4606762  PMID: 26437734

Abstract

Objectives

To estimate the proportion and numbers of cancers occurring in Australia attributable to solar ultraviolet radiation (UVR) and the proportion and numbers prevented by regular sun protection factor (SPF) 15+ sunscreen use.

Methods

We estimated the population attributable fraction (PAF) and numbers of melanomas and keratinocyte cancers (i.e. basal cell carcinomas and squamous cell carcinomas) due to exposure to ambient UVR resulting from residing in Australia versus residing in the UK (for melanoma) or Scandinavia (for keratinocyte cancers). We also estimated the prevented fraction (PF): the proportion of cancers that would have occurred but were likely prevented by regular sunscreen use.

Results

An estimated 7,220 melanomas (PAF 63%) and essentially all keratinocyte cancers occurring in Australia were attributable to high ambient UVR levels in Australia. We estimated that regular sunscreen use prevented around 14,190 (PF 9.3%) and 1,730 (PF 14%) people from developing SCC and melanoma, respectively.

Conclusions

Although our approach was conservative, a high proportion of skin cancers in Australia are attributable to high ambient levels of UVR. Prevailing levels of sunscreen use probably reduced skin cancer incidence by 10–15%.

Implications

Most skin cancers are preventable. Sunscreen should be a component of a comprehensive sun protection strategy.

Keywords: population attributable fraction, melanoma, skin cancer, solar radiation, sunscreen


In 1992, the International Agency for Research on Cancer (IARC) concluded that ultraviolet radiation (UVR) was carcinogenic to humans.1 The main source of exposure to UVR is the sun (solar radiation). In 2009, IARC confirmed that there is sufficient evidence that solar radiation causes cutaneous malignant melanoma, and squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the skin.2

Exposure to UVR can also occur through artificial sources, including UV-emitting tanning devices (solaria), medical and dental applications and industrial sources (e.g. electric arc welders, and some fluorescent and tungsten–halogen lamps). IARC has concluded that these artificial sources of UVR are also carcinogenic to humans.2 In Australia, the overwhelming source of UVR is from the sun. Despite the importance of artificial UVR exposures, this analysis focuses on quantifying the contributions of natural UV exposure to the incidence of human cancer.

Epidemiological evidence for the causal role of solar UVR exposure in the development of melanoma and keratinocyte cancers (basal cell carcinomas [BCC] and squamous cell carcinomas [SCC] of the skin) includes observations of higher incidence rates in fair-skinned, sun-sensitive people than dark-skinned people, and higher incidence in locations closer to the equator.3,4 Fair-skinned migrants from high to low latitude countries have a lower melanoma incidence rate than fair-skinned, native-born residents, and vice versa.5,6 In addition, people with a past history of keratinocyte cancer7 or solar keratoses8,9 (widely considered as markers of accumulated sun exposure and phenotypic sensitivity) have markedly higher risks of melanoma than people with no history of keratinocyte cancers. Molecular studies have identified UV-specific mutations in the DNA of key regulatory genes in melanomas.10,11 These epidemiologic observations are supported by a strong body of experimental evidence including animal, cellular and molecular studies.

Randomised trials have demonstrated that regular sunscreen use reduces the incidence of solar keratoses,12 SCC13 and possibly melanoma14 in susceptible individuals. Interestingly, and despite the conclusive evidence that solar UVR causes BCC, the only trial to examine this endpoint observed no effect of regular sunscreen on BCC incidence.13,15 Various explanations for the null result are possible, such as the ‘critical period’ for sunlight on BCC was at younger ages than the lowest age for trial entry or that sunscreen really has no effect, but these remain to be explored. Based on current knowledge, we can conclude only that sunscreen prevents SCC, possibly prevents melanoma and its effect on BCC is uncertain.

Here, we estimated the population attributable fractions (PAF) and numbers of cutaneous melanomas and keratinocyte cancers arising in the Australian population that were attributable to exposure to solar radiation. We also estimated the proportion of melanomas and cutaneous SCCs that were likely to have been prevented by regular sunscreen use in the Australian population (the ‘prevented fraction’, PF).

Methods

Solar UVR – population attributable fractions

In calculating the fractions of melanomas and keratinocyte cancers attributable to UVR, the traditional formula using population prevalence of exposure and relative risk of cancer is difficult to apply. This is because exposure to sunlight is ubiquitous and quantification of accumulated personal dose is prone to error. Instead, we adopted an approach similar to previous reports16,17 in which the fraction of melanoma cases attributable to solar UVR was calculated as the proportional difference between the melanoma incidence in ‘exposed’ and ‘unexposed’ populations of similar ethnic composition. While this method cannot provide a precise measure of the excess burden of melanoma due to any UVR exposure, we believe it provides a clearer sense of the burden due to high levels of ambient UVR experienced by the Australian population when compared to ethnically similar populations residing in environments with far lower levels of ambient UVR.18,19 The annual total UVR in Australian cities is about 3–5 times higher than reported for the UK (e.g. 9,760 standard erythermal dose [SED] for Sydney and 2,950 SED for Leeds).20

We used the following formula to calculate the PAF:

graphic file with name azph0039-0471-m1.jpg

where Ip is the incidence of melanoma in the Australian population, and Iu is the incidence in the reference population.

For our primary melanoma analysis, we estimated the difference between the observed numbers of melanoma cases in Australian residents21 (i.e. ‘exposed’ to high ambient UVR in Australia) and the expected number of cases assuming the population was exposed to levels of ambient UVR experienced by an ‘ancestral’ population for many Australians. As our reference, we used the UK population (2009–11).22 This reference population was chosen on the basis that the majority of susceptible Australian residents trace their ancestry to northern Europe, and particularly the British Isles,23 and because the difference in average ambient UV levels in each location is substantial.24,25 As a sensitivity analysis we used the same reference population as Parkin and colleagues17(i.e. the 1903 birth cohort from the South Thames, UK).

The total number of cancers attributable to UVR was also expressed as a percentage of the total number of all incident cancers (excluding basal cell and squamous cell carcinoma of the skin) recorded in the Australian population (children and adults) in 2010.

Potential impact of changing UVR exposure in the Australian population

In our primary analyses, we used the contemporary UK population as the comparator, which generated a PAF representing the maximum but unattainable target for solar protection strategies in the Australian population. To estimate the fraction of melanomas that might feasibly be prevented by population-wide behaviour change, we performed additional analyses:

  1. ‘Time shift’ analysis: the melanoma incidence rates experienced by the Australian population in 1982 were applied to the 2010 Australian Estimated Resident Population.

  2. ‘Geographic shift’ analysis: we estimated the number of melanomas that would have occurred if the population residing in each state or territory experienced melanoma at the rate of the population in the nearest state with lower melanoma incidence. For Queensland, we used New South Wales incidence rates;26 for New South Wales, Australian Capital Territory, and Western Australia, we used Victorian incidence rates;27 for Victoria and the Northern Territory we used South Australian incidence rates,28 since rates in South Australia were the lowest in mainland Australia (see supplementary file: Table S1, available with the online version of this article). South Australia and Tasmania were unchanged.

We used a similar approach to calculate the population fraction of keratinocyte cancers attributable to solar UVR (i.e. calculating the proportional difference between incidence in ‘highly sun exposed’ Australian population and ‘minimally sun exposed’ Scandinavian populations). We sourced incidence rates from the 2002 National Non-melanoma Skin Cancer Survey.29 The choice of a reference population was limited by the availability of reliable incidence data; we used incidence rates from Nordcan for all participating countries (Denmark, Sweden, Norway, Finland, Iceland and the Faroe Islands).30 Incidence rates of BCC and SCC were not provided separately in the Nordcan database, so analyses were conducted for all keratinocyte cancers combined. We performed a sensitivity analysis using the 2002 time period. While more reliable than most countries, incidence of keratinocyte cancers in Nordcan may be under-reported by up to 30%,31 so we performed a sensitivity analysis assuming this extent of under-reporting.

Sunscreen-prevented fractions

Relative Risk estimates

The relative risk estimate for the protective effect of regular sunscreen use on SCCs of the skin was sourced from long-term follow-up of participants of the Nambour Skin Cancer Prevention Trial.15 The Nambour trial commenced in 1992 and randomised 1,621 participants to receive either regular application of broad-spectrum sunscreen (SPF 16) to the head, neck, arms and hands (intervention arm) or discretionary sunscreen (control arm).14,15 The age range for trial participants was 25–75 (median 48 years). We used the relative risk for SCC incidence (persons affected) over 11 years from commencement of the intervention15 (RR=0.65, 95%CI 0.45–0.94).

The evidence that regular sunscreen use prevents melanoma is weaker than for SCC. Again, we sourced effect estimates from the only randomised trial to assess the efficacy of sunscreen on melanoma, the Nambour Skin Cancer Prevention Trial, which reported a marginally significant reduced incidence among regular sunscreen users (RR=0.50, 95%CI 0.24–1.02).14

Exposure prevalence estimates

We sought population-based prevalence estimates for sunscreen use that best aligned with the intervention delivered in the randomised trial. Of several possible sources of data, we selected the 2010 NSW Population Health Survey as best meeting this criterion.32 As the NSW sunscreen prevalence data may not have reflected national patterns of sunscreen use (or use during earlier time periods arguably more relevant to melanoma development), we used prevalence data from other population-based surveys to conduct sensitivity analyses: the NSW Population Health Survey 2004,33 Victorian Sun Survey 2006–07,34 Queensland Self-reported Health Status for 2009,35 and the National Sun Protection Survey 2010–11.36 The questions relating to sunscreen use in each of these surveys are summarised in supplementary file: Table S2, available online.

Cancer incidence data

Using age-specific rates obtained from the 2002 National Non-melanoma Skin Cancer Survey29 and the estimated resident population for 2008, it was estimated that there were 83,901 new cases of SCC of the skin in men and 53,699 new cases of SCC of the skin in women in 2008.29 For consistency with the SCC analyses, we used incidence data for 2008 for melanoma of the skin (11,029 cases).29

Statistical analysis

As sunscreen has a protective effect, and as the natural exposure level is zero, the Prevented Fraction (PF) is the most appropriate measure to quantify population impact:

graphic file with name azph0039-0471-m2.jpg

where Px is the prevalence of regular sunscreen use by sex category.

We estimated the number of SCCs prevented through regular sunscreen use using the following formula:

graphic file with name azph0039-0471-m3.jpg

where Nx is the number of observed cancers in 2008 in each sex category and PFx is the prevented fraction in each sex category.

The overall prevented fraction was then calculated by summing the total number of prevented SCCs or melanomas across all categories of age and sex, and expressing this sum as a percentage of the total numbers of observed plus prevented cancers.

Results

Solar UVR

Number and proportion of melanomas attributable to ambient UVR exposure

In our primary analysis applying contemporary UK melanoma rates to the Australian population, 7,220 melanomas in 2010 (4,668 in men and 2,552 in women) were attributable to the ambient UVR exposure experienced by Australian residents. This represents 63% of the observed melanoma cases in Australia in that year (Table 1). Our sensitivity analysis using the historical UK comparison (i.e. the 1903 birth cohort from the South Thames, UK) resulted in a PAF of 95% (97% for men and 92% for women).

Table 1.

Number and fraction of cutaneous melanoma cases diagnosed in Australia in 2010 attributable to the difference in ambient UVR exposure between Australia and the United Kingdom

Melanoma (C43) All cancera

Age(years) Expected Cases Observed cases Excess attributable cases Observed cases Excess attributable cases


No. % No. %
Males

0–4 0 1 1 100.0 159 1 0.8
5–9 0 0 0 0.0 85 0 0.1
10–14 1 3 2 48.5 85 2 1.6
15–19 8 17 9 54.9 176 9 5.3
20–24 21 43 22 50.6 310 22 7.0
25–29 43 105 62 58.9 448 62 13.8
30–34 58 158 100 63.0 595 100 16.7
35–39 79 220 141 63.9 889 141 15.8
40–44 114 286 172 60.4 1,324 172 13.1
45–49 137 402 265 65.8 2,448 265 10.8
50–54 169 566 397 70.1 4,184 397 9.5
55–59 195 688 493 71.7 6,691 493 7.4
60–64 257 845 588 69.5 9,588 588 6.1
65–69 228 817 589 72.1 10,143 589 5.8
70–74 232 800 568 70.9 9,370 568 6.1
75–79 201 683 482 70.6 7,960 482 6.1
80–84 157 619 462 74.7 6,560 462 7.1
85+ 132 447 315 70.5 4,968 315 6.3
TOTAL 2,032 6,700 4,668 69.6% 65,983 4,668 7.1%

Females

0–4 0 0 0 0.0 147 0 0.1
5–9 0 1 1 100.0 50 1 1.8
10–14 1 4 3 84.7 77 3 4.9
15–19 12 18 6 29.4 138 6 3.8
20–24 45 61 16 26.5 236 16 6.9
25–29 81 157 76 48.3 568 76 13.3
30–34 108 180 72 40.1 833 72 8.7
35–39 142 248 106 43.0 1,494 106 7.2
40–44 173 317 144 45.3 2,142 144 6.7
45–49 196 402 206 51.2 3,416 206 6.0
50–54 199 443 244 55.1 4,396 244 5.6
55–59 202 471 269 57.2 5,038 269 5.3
60–64 226 523 297 56.9 6,004 297 5.0
65–69 187 471 284 60.2 5,859 284 4.8
70–74 164 365 201 55.1 5,214 201 3.8
75–79 142 367 225 61.3 4,958 225 4.5
80–84 133 321 188 58.7 4,862 188 3.9
85+ 142 356 214 60.1 5,166 214 4.1
TOTAL 2,153 4,705 2,552 54.3% 50,598 2,552 5.0%

Persons

0–4 0 1 1 100.0 306 1 0.5
5–9 0 1 1 0.0 135 1 0.7
10–14 2 7 5 70.8 162 5 3.2
15–19 20 35 15 42.0 313 15 4.6
20–24 66 104 38 36.5 545 38 7.0
25–29 124 262 138 52.5 1,015 138 13.5
30–34 166 338 172 50.8 1,428 172 12.0
35–39 221 468 247 52.8 2,384 247 10.4
40–44 287 603 316 52.4 3,467 316 9.1
45–49 333 804 471 58.5 5,864 471 8.0
50–54 368 1,009 641 63.5 8,580 641 7.5
55–59 397 1,159 762 65.8 11,729 762 6.5
60–64 483 1,368 885 64.7 15,592 885 5.7
65–69 415 1,288 873 67.7 16,003 873 5.5
70–74 396 1,165 769 66.0 14,584 769 5.3
75–79 343 1,050 707 67.4 12,918 707 5.5
80–84 290 940 650 69.2 11,422 650 5.7
85+ 274 803 529 65.9 10,134 529 5.2
TOTAL 4,185 11,405 7,220 63.3% 116,580 7,220 6.2%

a excluding basal cell carcinoma and squamous cell carcinoma of the skin

Potential impact of changing UVR exposure in the Australian population

The potential impact on melanoma incidence of reducing solar UVR exposure in the Australian population is summarised in Table 2.

Table 2.

Potential impact of changing solar UVR exposure: number of cutaneous melanomas (C43) and population attributable fractions (PAF)

Sex Observed Cases 2010 Time Shifta Geographic Shiftb

Expected Cases Excess cases PAF% Expected Cases Excess cases PAF%
Males 6,700 3,185 3,515 52.5 5,434 1,266 18.9

Females 4,705 3,072 1,633 34.7 3,951 754 16.0

Persons 11,405 6,257 5,148 45.1 9,385 2,020 17.7

a: Australian 1982 incidence rates as reference

b: Incidence rates of nearest lower level jurisdiction as reference for each State and Territory (South Australia and Tasmania unchanged)

Time shift analysis

Briefly, assuming an intervention was able to successfully decrease sun exposure such that the Australian adult population of 2010 had developed melanoma at the rates prevailing in 1982, we estimate that 5,148 fewer cases of melanoma would have occurred (a reduction in incidence of 45%).

Geographic shift analysis

Assuming a more modest intervention, whereby the incidence of melanoma in each state or territory was reduced to the incidence observed in the nearest state with lower incidence, we estimate that 2,020 fewer cases of melanoma would have occurred (incidence reduction 18%).

Number and proportion of keratinocyte cancers attributable to ambient UVR exposure

When the age- and sex-specific incidence rates for keratinocyte cancer from the Nordic countries for 2002 were applied to the Australian population (2002), virtually 100% of keratinocyte skin cancers were attributable to sun exposure. Assuming that keratinocyte cancers were under-reported by 30% in the Nordcan database made no material difference to the PAF estimates (99.4% using 2002 incidence rates).

Sunscreen

Prevalence of regular sunscreen use

The New South Wales Population Health Survey (2010) reported that 28% of participants always applied a broad-spectrum sunscreen (SPF 15+) to exposed skin when they were out in the sun for longer than 15 minutes.32 The proportion of women (35%) who applied sunscreen regularly was higher than men (21%).32

Proportion of keratinocyte cancers and melanomas prevented due to regular sunscreen use

Assuming the prevalence of regular sunscreen use above and the protective effects reported in the long-term follow-up of the Nambour trial, we estimated that 9.3% of Australians who would otherwise have developed cutaneous SCC in 2008 had their cancers prevented through regular sunscreen use, equating to 14,192 people (Table 3). Similarly, about 14% of people who would otherwise have developed melanoma in 2008 had their cancers prevented through regular sunscreen use; that is 1,729 prevented cases. Table 3 summarises the prevented fraction, and estimated number of prevented cases of cutaneous SCC of the skin, when other sources of sunscreen prevalence were used. In all instances, the estimated prevented fractions of SCC were higher than those derived using 2010 NSW Population Health Survey data and ranged from 11% to 17%.

Table 3.

Summary of results: prevented fraction and number of cutaneous SCCs prevented (2010) through regular sunscreen use, primary and sensitivity analyses

Estimated Cancer incidence (2008)a Primary analysis >Sensitivity analyses

NSW Population Health Survey 2010 NSW Population Health Survey 2004 Victorian Sun Survey 2006–07 Queensland Self-reported Health Status 2009 National Sun Protection Survey 2010–11

% Sun-screen Use PFb Cancers prevented % Sun-screen Use PFb Cancers prevented % Sun-screen Use PFb Cancers prevented % Sun-screen Use PFb Cancers prevented % Sun-screen Use PFb Cancers prevented
Males 83,901 21.4 7.5 6,793 40.9 14.3 14,017 27.0 9.5 8,379 39.1 11.2 10,602 36.0 12.6 12,096

Females 53,699 34.6 12.1 7,399 59.5 20.8 14,124 44.0 15.4 9,385 51.8 15.0 9,462 36.0 12.6 7,742

Persons 137,600 9.3 14,192 17.0 28,141 11.4 17,764 12.7 20,064 12.6 19,837

a: Source: Australian Institute of Health and Welfare29

b: PF: Prevented Fraction (expressed as a percentage)

Discussion

UVR is the major environmental cause of melanoma and keratinocyte cancers. We estimate that 63% of all melanomas and virtually all keratinocyte cancers could be attributed to the high background levels of UVR experienced by the Australian resident population. We also estimated that the number of people diagnosed with SCC in the Australian adult population in 2008 was reduced by at least 9.3% (or about 14,200 cases) because of prevailing levels of sunscreen use. Similarly, our analyses suggest that melanoma incidence was about 14% lower than would otherwise have been observed because of sunscreen use, assuming that regular sunscreen use prevents this cancer.

We employed a similar approach to previous evaluations of the fraction of melanoma cases related to UVR exposure,16,17 although our choice of an ‘unexposed’ or ‘reference’ population differed from those earlier reports. Armstrong and Kricker16 modelled three alternative exposed/unexposed populations: the first compared incidence in white Americans with incidence in black Americans (assumed to be the incidence in unexposed whites) – PAFs 96% for males and 92% for females; the second compared incidence rates in Australians to those in migrants from areas of lower ambient UVR (overall PAF 68%); and the third compared the incidence of melanoma on all body sites to the incidence on unexposed body sites (buttocks and, in women only, the scalp) – PAFs 97% in males and 96% in females. Thus, our estimate of 63% of melanomas arising in Australia were attributable to the higher UVR levels to which the population are exposed is similar in magnitude to the estimate of Armstrong and Kricker using similar methods.37 Parkin and colleagues17 used historical data from the South Thames region of England, defining the 1903 birth cohort as the “minimum risk” population and estimated PAFs of 90% in males and 82% in females.

For our primary analysis, we used the contemporary UK population as our reference to reduce possible bias introduced by changes in modes of diagnosis and cancer registration that almost certainly apply to historic datasets. Nonetheless, our choice of reference population was conservative, and is likely to underestimate the ‘true’ fraction of melanomas attributable to ambient sunlight. This is because the reference population is not ‘unexposed’ to UVR but rather ‘less exposed than the Australian population’. Hence, the fraction we estimated was the proportion of melanomas attributable to residing in Australia rather than England. As shown by Parkin,17 however, around 90% of melanomas in the UK can also be attributed to sun exposure. Thus, to estimate the ‘true’ fraction of melanomas in Australia attributable to any sun exposure would require comparison with a cohort that had very limited sun exposure. We are not aware of any contemporaneous cohorts that would meet this criterion, so we conducted further sensitivity analyses using the same population as Parkin and colleagues17 (i.e. the 1903 birth cohort from the South Thames, UK) which resulted in a PAF more comparable with that reported by Parkin.17

A limitation of the analyses for keratinocyte cancers is the lack of reliable national incidence data, both for Australia and international comparator populations. Most Australian states and territories do not capture notifications of keratinocyte cancers, and other health registers (e.g. Medicare) do not record details of skin cancer histology. We therefore used data from a 2002 National Survey to estimate Australian incidence rates,29 and we used Scandinavian registry data for comparisons. Although the Scandinavian registries are considered some of the most complete, they are also subject to a degree of under-reporting.38,39 This may have resulted in an inflated estimate of the proportion of keratinocyte cancers attributable to UVR.

Although the numbers of cancers attributable to UV generated by these analyses may appear precise, we remind readers that there is potential for error in these estimates due both to statistical uncertainty (precision) as well as variation in prevalence and risk estimates. We did not calculate confidence intervals for the PAF as these is no universally agreed approach. Instead, we performed sensitivity analyses under various scenarios, which convey a sense of the range of uncertainty of our estimates.

We did not calculate PAFs associated with solarium use. While solarium use in Australia grew in popularity in the 1990s and early 2000s,40 publicity and active campaigning has recently seen the number of solaria decline. In addition, all Australian states and territories except Western Australia and Northern Territory had passed legislation to ban solaria (except for medical use in Tasmania) by the end of 2014.41

Very few data are available with which to estimate the effectiveness of sunscreen for preventing skin cancers. We used data from the only trial of sunscreen use and skin cancer ever conducted.13,15 While the relative risk estimates from that trial were generated from a 5-year intervention with 11 years of follow-up, it is possible that the observed effect of sunscreen on skin cancer incidence may have been greater had there been longer follow-up and a greater age span. If so, our calculations of prevented fraction may be underestimates. Further, while we assumed that regular sunscreen use exerts the same magnitude of effect at all ages; it is possible that it may have different magnitudes of effect on younger or older people. For melanoma, UV exposure in early life is thought to be particularly important,5 and thus sunscreen use among children and adolescents may lead to even greater benefits in cancer prevention and may include BCC prevention.

The estimates of prevalence of sunscreen use applied in our primary analysis (from the 2010 NSW Population Health Survey) were chosen because the question most closely reflected the administration of sunscreen in the Nambour trial. The NSW Population Health Survey was a survey of 10,245 adults aged 16 years and over with a participation rate of 57%.32 The survey was conducted by telephone, so respondents were all from households with private telephones; and adult males were under-represented (40% of the sample versus 50% of the NSW adult population).32 We conducted sensitivity analyses using prevalence data from other Australian surveys and the resulting prevented fractions were similar to those from our primary analysis.

We acknowledge counter-arguments that relate to potential harm associated with sunscreen use, including the potential to extend intentional sun exposure42 and a potential effect on vitamin D production, although evidence for the latter is lacking.43 For the Australian population, where knowledge about skin cancer and sun protection is high,44 it is not known whether sunscreen is used to extend intentional sun exposure. The Nambour trial found no increase in sun exposure for the group randomised to sunscreen and, regardless, there was a net benefit for SCC of the skin associated with regular sunscreen use, and possibly also for melanoma.

The high proportion of melanomas and keratinocyte cancers attributable to solar UVR exposure underscores the potential for preventing these cancers. High sun exposure is modifiable through various practices including minimising outdoor activity during periods of peak ambient UVR (such as in summer and in the middle hours of the day), wearing sun-protective clothing and applying sunscreen. The analyses here indicate that prevailing levels of sunscreen are likely to have substantially reduced the incidence of SCC and perhaps also melanoma. More widespread regular use would be expected to reduce the incidence further. At a population level, it has recently been shown that treatment rates for keratinocyte skin cancers declined over the period 2000–11 among Australians aged under 45 years.45 One interpretation of those data is that skin cancer prevention programs that have been prominent in Australia for more than 30 years have led to changes in sun protection among more recent birth cohorts.46 Continued monitoring of these trends will be important to determine whether they are sustained into the future.

Acknowledgments

This work was supported by a grant from Cancer Council Australia. REN, LF and DCW were supported by Research Fellowships from the National Health and Medical Research Council of Australia (NHMRC). CMO was supported by a NHMRC Program Grant (552429). The funding bodies had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation, review, or approval of the manuscript.

We thank Dr Peter Gies, Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) for helpful comments on the draft manuscript.

CMO and LFW contributed equally to this manuscript and share first authorship.

PAF Project

Chief Investigators: David C. Whiteman, Penelope M. Webb, Adele C. Green, Rachel E. Neale, Lin Fritschi

Associate Investigators: Louise F. Wilson, Catherine M. Olsen, Christina M. Nagle, Nirmala Pandeya, Susan J. Jordan, Annika Antonsson, Bradley J. Kendall, Torukiri I. Ibiebele, Maria Celia B. Hughes, Kyoko Miura, Susan Peters, Renee N. Carey

Advisers: Christopher J. Bain, D. Max Parkin

Supporting Information

Additional supporting information may be found in the online version of this article:

Supplementary Table 1: Theoretical “geographic shift” in State and Territory incidence (/100,000) of melanoma.

Supplementary Table 2: Summary of questions about sunscreen use in State and National Health Surveys.

azph0039-0471-sd1.docx (27.8KB, docx)

References

  • 1.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 1992. Solar and Ultraviolet Radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 55. Lyon (FRC): World Health Organisaton.
  • 2.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2012. A Review of Human Carcinogens. IARC Monographs – Radiation. Vol 100D. Lyon (FRC): World Health Organisation.
  • 3.Green AE, Findley GB, Jr, Klenk KF, Wilson WM, Mo T. The ultraviolet dose dependence of non-melanoma skin cancer incidence. Photochem Photobiol. 1976;24(4):353–62. doi: 10.1111/j.1751-1097.1976.tb06836.x. [DOI] [PubMed] [Google Scholar]
  • 4.Whiteman DC, Pavan WJ, Bastian BC. The melanomas: A synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011;24(5):879–97. doi: 10.1111/j.1755-148X.2011.00880.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: A systematic review of epidemiologic studies. Cancer Causes Control. 2001;12(1):69–82. doi: 10.1023/a:1008980919928. [DOI] [PubMed] [Google Scholar]
  • 6.Armstrong BKT, Woodings TL, Stenhouse NS, McCall MG. Mortality from Cancer Migrants to Australia – 1962-1971. Perth (AUST): University of Western Australia Department of Medicine Raine Medical Statistics Unit; 1983. [Google Scholar]
  • 7.Green AC, O'Rourke MG. Cutaneous malignant melanoma in association with other skin cancers. J Natl Cancer Inst. 1985;74(5):977–80. [PubMed] [Google Scholar]
  • 8.Chang YM, Barrett JH, Bishop DT, Armstrong BK, Bataille V, Bergman W, et al. Sun exposure and melanoma risk at different latitudes: A pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol. 2009;38(3):814–30. doi: 10.1093/ije/dyp166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bataille V, Sasieni P, Grulich A, Swedlow A, McCarthy W, Hersey P, et al. Solar keratoses: A risk factor for melanoma but negative association with melanocytic naevi. Int J Cancer. 1998;78(1):8–12. doi: 10.1002/(sici)1097-0215(19980925)78:1<8::aid-ijc2>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 10.Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191–6. doi: 10.1038/nature08658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Brash DE. UV Signature Mutations. Photochem Photobiol. 2015;91(1):15–26. doi: 10.1111/php.12377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329(16):1147–51. doi: 10.1056/NEJM199310143291602. [DOI] [PubMed] [Google Scholar]
  • 13.Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial. Lancet. 1999;354(9180):723–9. doi: 10.1016/S0140-6736(98)12168-2. [DOI] [PubMed] [Google Scholar]
  • 14.Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: Randomized trial follow-up. J Clin Oncol. 2011;29(3):257–63. doi: 10.1200/JCO.2010.28.7078. [DOI] [PubMed] [Google Scholar]
  • 15.van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2546–8. doi: 10.1158/1055-9965.EPI-06-0352. [DOI] [PubMed] [Google Scholar]
  • 16.Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res. 1993;3:395–401. doi: 10.1097/00008390-199311000-00002. [DOI] [PubMed] [Google Scholar]
  • 17.Parkin DM, Mesher D, Sasieni P. Cancers attributable to solar(ultraviolet) radiation exposure in the UK in 2010. Br J Cancer. 2011;105:S66–S69. doi: 10.1038/bjc.2011.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Australian Bureau of Statistics. 2071.0 – Reflecting a Nation: Stories from the 2011 Census, 2012-2013 [Internet] Canberra (AUST): ABS; 2012. [cited 2015 Jul 13]. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/lookup/2071.0main+features902012-2013. [Google Scholar]
  • 19.Office for National Statistics. Ethnicity and National Identity in England and Wales 2011 [Internet] Newport (South Wales): ONS; 2012. [cited 2015 Jul 13]. Available from: http://www.ons.gov.uk/ons/rel/census/2011-census/key-statistics-for-local-authorities-in-england-and-wales/rpt-ethnicity.html#tab-conclusions. [Google Scholar]
  • 20.Gies P, Roy C, Javorniczky J, Henderson S, Lemus-Deschamps L, Driscoll C. Global Solar UV Index: Australian measurements, forecasts and comparison with the UK. Photochem Photobiol. 2004;79(1):32–9. [PubMed] [Google Scholar]
  • 21.Australian Institute of Health and Welfare. Cancer Data. Pivot Table [Internet] Canberra (AUST): AIHW; 2015. [cited 2014 Jun 23]. Available from: http://www.aihw.gov.au/cancer-data/ [Google Scholar]
  • 22.Cancer Research UK. Skin Cancer Incidence Statistics [Internet] London (UK): CR-UK; 2014. [cited 2014 May 28]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/skin-cancer/incidence#heading-One. [Google Scholar]
  • 23.Khoo S, Lucas D. Australian Census Analytic Program: Australians' Ancestries 2001. Canberra (AUST): Australian Bureau of Statistics; 2004. [Google Scholar]
  • 24.Diffey BL, Gies HP. The confounding influence of sun exposure in melanoma. Lancet. 1998;351(9109):1101–2. doi: 10.1016/s0140-6736(05)79381-8. [DOI] [PubMed] [Google Scholar]
  • 25.Elwood JM, Diffey BL. A consideration of ambient solar ultraviolet radiation in the interpretation of studies of the aetiology of melanoma. Melanoma Res. 1993;3(2):113–22. [PubMed] [Google Scholar]
  • 26.Currow D, Thomson W. Cancer in NSW: Incidence Report 2009. Sydney (AUST): Cancer Institute in NSW; 2014. 2014. [Google Scholar]
  • 27.Thursfield V, Farrugia H. Cancer in Victoria: Statistics and Trends 2010 [Internet] Melbourne (AUST): Cancer Council Victoria; 2011. [cited 2013 Jul 10]. Available from: http://www.cancervic.org.au/downloads/cec/cancer-in-vic/CCV-Statistics-trends.pdf. [Google Scholar]
  • 28.South Australian Cancer Registry. Cancer in South Australia 2009 – with Projections to 2012 [Internet] Adelaide (AUST): South Australian Health; 2013. [cited 2013 Jul 10]. Available from: http://www.sahealth.sa.gov.au/wps/wcm/connect/48188b804fc4c928a01cba5cbc1ea1e9/CancerInSA2009-Epidemiology-20130601.pdf?MOD=AJPERES&CACHEID=48188b804fc4c928a01cba5cbc1ea1e9. [Google Scholar]
  • 29.Cancer Australia. Cancer Series No.: 43. Canberra (AUST): AIHW; 2008. Non-melanoma Skin Cancer: General Practice Consultations, Hospitalisation and Mortality. [Google Scholar]
  • 30.Engholm G, Ferlay J, Christensen N, Johannesen TB, Khan S, Køtlum JE, et al. NORDCAN: Cancer Incidence, Mortality and Prevalence in the Nordic Countries. Ver 6.1 [Internet] Copenhagen (DMK): Association of the Nordic Cancer Registries; 2014. [cited 2014 Jun 2]. Available from: http://www.ancr.nu. [Google Scholar]
  • 31.Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjaer SK. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: Rapid incidence increase among young Danish women. Int J Cancer. 2010;127(9):2190–8. doi: 10.1002/ijc.25411. [DOI] [PubMed] [Google Scholar]
  • 32.Centre for Epidemiology and Research. 2010 Report on Adult Health from the New South Wales Population Health Survey. Sydney (AUST): New South Wales Department of Health; 2011. [Google Scholar]
  • 33.Centre for Epidemiology and Research, NSW Department of Health. N S W Public Health Bull. 2005;16:S–1. 2004 Report on Adult Health from the New South Wales Population Health Survey. [Google Scholar]
  • 34.Makin JK, Warne CD, Dobbinson SJ, Wakefield MA, Hill DJ. Population and age-group trends in weekend sun protection and sunburn over two decades of the SunSmart programme in Melbourne, Australia. Br J Dermatol. 2013;168(1):154–61. doi: 10.1111/bjd.12082. [DOI] [PubMed] [Google Scholar]
  • 35.Queensland Department of Health. Self Reported Health Status 2009, 2010, 2011, 2012. Brisbane (AUST): Unpublished observations; 2014.
  • 36.Volkov A, Dobbinson S, Wakefield M, Slevin T. Seven-year trends in sun protection and sunburn among Australian adolescents and adults. Aust N Z J Public Health. 2013;37(1):63–9. doi: 10.1111/1753-6405.12012. [DOI] [PubMed] [Google Scholar]
  • 37.Kricker A, Armstrong BK, English DR. Sun exposure and non-melanocytic skin cancer. Cancer Causes Control. 1994;5(4):367–92. doi: 10.1007/BF01804988. [DOI] [PubMed] [Google Scholar]
  • 38.Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN-a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–36. doi: 10.3109/02841861003782017. [DOI] [PubMed] [Google Scholar]
  • 39.Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: A prospective cohort study. J Invest Dermatol. 2013;133(3):629–36. doi: 10.1038/jid.2012.395. [DOI] [PubMed] [Google Scholar]
  • 40.Makin JK, Dobbinson S, Herd NL. The increase in solariums in Australia, 1992-2006. Aust N Z J Public Health. 2007;31(2):191–2. doi: 10.1111/j.1753-6405.2007.00042.x. [DOI] [PubMed] [Google Scholar]
  • 41.Cancer Council Australia. Position Statement. Solariums [Internet] Sydney (AUST): CCA; 2013. 2013, [cited 11 March 2014]. [cited 2014 Mar 11]. Available from: http://wiki.cancer.org.au/prevention/Position_statement_-_Solariums. [Google Scholar]
  • 42.International Agency for Research on Cancer Working Group. Attributable Causes of Cancer in France in the Year 2000. Lyon (FRC): World Health Organization; 2007. [Google Scholar]
  • 43.Burnett ME, Wang SQ. Current sunscreen controversies: A critical review. Photodermatol Photoimmunol Photomed. 2011;27(2):58–67. doi: 10.1111/j.1600-0781.2011.00557.x. [DOI] [PubMed] [Google Scholar]
  • 44.Baade PD, Balanda KP, Lowe JB. Changes in skin protection behaviors, attitudes, and sunburn: In a population with the highest incidence of skin cancer in the world. Cancer Detect Prev. 1996;20(6):566–75. [PubMed] [Google Scholar]
  • 45.Olsen CM, Williams PF, Whiteman DC. Turning the tide? Changes in treatment rates for keratinocyte cancers in Australia 2000 through 2011. J Am Acad Dermatol. 2014;71(1):21–6. doi: 10.1016/j.jaad.2014.02.011. e1. [DOI] [PubMed] [Google Scholar]
  • 46.Iannacone MR, Green AC. Towards skin cancer prevention and early detection: Evolution of skin cancer awareness campaigns in Australia. Melanoma Manag. 2014;1(1):75–84. doi: 10.2217/mmt.14.6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Table 1: Theoretical “geographic shift” in State and Territory incidence (/100,000) of melanoma.

Supplementary Table 2: Summary of questions about sunscreen use in State and National Health Surveys.

azph0039-0471-sd1.docx (27.8KB, docx)

Articles from Australian and New Zealand Journal of Public Health are provided here courtesy of Wiley

RESOURCES